Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and PK of BEA 2180 BR in Healthy Males
NCT02258971Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2007
- Primary completion
- May 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of bea 2180 in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Individual time course profiles of [14C] radioactivity up to 312 hours, Individual time course profiles of BEA 2180 and its metabolites CD 1975 ZW and CD 1976 ZW up to 312 hours and 17 more. Started Mar 2007; status: completed.
02
Drugs
bea 2180
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02258971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258971.